Karyopharm Therapeutics (KPTI) News Today $0.78 0.00 (0.00%) (As of 11/20/2024 ET) Add Compare Share Share Headlines Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSustainabilityTrends All Sources Trusted Sources MarketBeat.com Benzinga Bloomberg GuruFocus MarketWatch Motley Fool NASDAQ PR Newswire Reuters Seeking Alpha The Street TipRanks The Wall Street Journal Yahoo Finance Source Sentiment refers to the positivity or negativity of each headline according to our language processing algorithm. Sentiment All Sentiments Very Positive Positive Neutral Negative Very Negative Most Recent November 2024 October 2024 September 2024 August 2024 July 2024 June 2024 May 2024 April 2024 March 2024 February 2024 January 2024 December 2023 November 2023 October 2023 September 2023 August 2023 July 2023 June 2023 May 2023 April 2023 March 2023 February 2023 January 2023 December 2022 November 2022 October 2022 September 2022 August 2022 July 2022 June 2022 May 2022 April 2022 March 2022 February 2022 January 2022 December 2021 Time Period Karyopharm Therapeutics Announces the Appointment of Chief Accounting OfficerNovember 20 at 4:20 PM | prnewswire.comKaryopharm to Present Selinexor Data at the 66th American Society of Hematology Annual Meeting and ExpositionNovember 18 at 7:00 AM | prnewswire.comGSA Capital Partners LLP Purchases 792,283 Shares of Karyopharm Therapeutics Inc. (NASDAQ:KPTI)GSA Capital Partners LLP increased its holdings in Karyopharm Therapeutics Inc. (NASDAQ:KPTI - Free Report) by 80.6% in the third quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The firm owned 1,775,700 shares of the company's stockNovember 14, 2024 | marketbeat.comKaryopharm Therapeutics (NASDAQ:KPTI) Stock Rating Upgraded by StockNews.comStockNews.com upgraded shares of Karyopharm Therapeutics from a "hold" rating to a "buy" rating in a research report on Thursday.November 14, 2024 | marketbeat.comStrategic Clinical Advances and Revenue Growth Drive Buy Rating for Karyopharm TherapeuticsNovember 9, 2024 | markets.businessinsider.comKaryopharm Therapeutics Inc. (NASDAQ:KPTI) Just Reported Third-Quarter Earnings: Have Analysts Changed Their Mind On The Stock?November 8, 2024 | finance.yahoo.comLeerink Partnrs Has Optimistic Outlook of KPTI Q4 EarningsKaryopharm Therapeutics Inc. (NASDAQ:KPTI - Free Report) - Equities researchers at Leerink Partnrs boosted their Q4 2024 earnings per share (EPS) estimates for shares of Karyopharm Therapeutics in a report released on Wednesday, November 6th. Leerink Partnrs analyst J. Chang now anticipates thatNovember 8, 2024 | marketbeat.comFY2024 Earnings Forecast for KPTI Issued By HC WainwrightKaryopharm Therapeutics Inc. (NASDAQ:KPTI - Free Report) - Investment analysts at HC Wainwright boosted their FY2024 earnings per share (EPS) estimates for Karyopharm Therapeutics in a note issued to investors on Tuesday, November 5th. HC Wainwright analyst E. White now expects that the company wNovember 8, 2024 | marketbeat.comKaryopharm Therapeutics Third Quarter 2024 Earnings: Beats ExpectationsNovember 6, 2024 | finance.yahoo.comKaryopharm price target raised to $5 from $4 at Piper SandlerNovember 6, 2024 | markets.businessinsider.comRBC Capital Sticks to Its Buy Rating for Karyopharm Therapeutics (KPTI)November 6, 2024 | markets.businessinsider.comPiper Sandler Raises Karyopharm Therapeutics (NASDAQ:KPTI) Price Target to $5.00Piper Sandler increased their price objective on Karyopharm Therapeutics from $4.00 to $5.00 and gave the stock an "overweight" rating in a research report on Wednesday.November 6, 2024 | marketbeat.comKaryopharm Therapeutics Inc (KPTI) Q3 2024 Earnings Call Highlights: Navigating Growth Amidst ...November 6, 2024 | finance.yahoo.comKaryopharm Therapeutics Inc. Reports Q3 2024 EarningsNovember 6, 2024 | markets.businessinsider.comKaryopharm Therapeutics: Strong Demand and Strategic Initiatives Justify Buy RatingNovember 6, 2024 | markets.businessinsider.comKaryopharm Therapeutics (KPTI) Q3 2024 Earnings Call TranscriptNovember 6, 2024 | msn.comKaryopharm Therapeutics Inc. (KPTI) Q3 2024 Earnings Call TranscriptNovember 5, 2024 | seekingalpha.comAntengene to Present Results from Two Late-Stage Studies of Selinexor Signaling Potential Clinical Breakthrough at ASH 2024November 5, 2024 | prnewswire.comKaryopharm Reports Third Quarter 2024 Financial Results and Highlights Recent Company ProgressNovember 5, 2024 | prnewswire.comKaryopharm changes endpoint in Phase 3 trial of selinexor in myelofibrosisNovember 1, 2024 | markets.businessinsider.comKaryopharm Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)November 1, 2024 | prnewswire.comKaryopharm Therapeutics (KPTI) to Release Earnings on TuesdayKaryopharm Therapeutics (NASDAQ:KPTI) will be releasing earnings before the market opens on Tuesday, November 5, Zacks reports.November 1, 2024 | marketbeat.comKaryopharm Therapeutics' (KPTI) Buy Rating Reiterated at HC WainwrightHC Wainwright reiterated a "buy" rating and issued a $7.00 price objective on shares of Karyopharm Therapeutics in a research note on Friday.November 1, 2024 | marketbeat.comPositive Developments and FDA Agreement Boost Karyopharm’s Buy RatingNovember 1, 2024 | markets.businessinsider.comKaryopharm to Report Third Quarter 2024 Financial Results on November 5, 2024October 31, 2024 | prnewswire.comKaryopharm Announces Favorable Change in Co-Primary Endpoint for Pivotal Phase 3 SENTRY Trial in MyelofibrosisOctober 31, 2024 | prnewswire.comKaryopharm to Host Investor Event with Leading Myelofibrosis KOLs and Provide a Favorable Study Design Update on October 31, 2024October 30, 2024 | prnewswire.comKaryopharm Therapeutics (NASDAQ:KPTI) Share Price Passes Below 200-Day Moving Average - Here's What HappenedKaryopharm Therapeutics (NASDAQ:KPTI) Share Price Passes Below 200-Day Moving Average - Here's WhyOctober 30, 2024 | marketbeat.comHighbridge Capital Management's Strategic Acquisition of Karyopharm Therapeutics SharesOctober 26, 2024 | finance.yahoo.comPiper Sandler Sticks to Their Buy Rating for Karyopharm Therapeutics (KPTI)October 23, 2024 | markets.businessinsider.comKaryopharm Therapeutics (NASDAQ:KPTI) Shares Pass Above 50-Day Moving Average - Here's What HappenedKaryopharm Therapeutics (NASDAQ:KPTI) Shares Cross Above Fifty Day Moving Average - Here's WhyOctober 22, 2024 | marketbeat.comAntengene Announces XPOVIO® (selinexor) Approved for Its Third Indication in South Korea, Bringing Fresh Hope to Patients with MM in the CountryOctober 17, 2024 | prnewswire.comKaryopharm Therapeutics Inc. (NASDAQ:KPTI) Holdings Lifted by AQR Capital Management LLCAQR Capital Management LLC grew its position in Karyopharm Therapeutics Inc. (NASDAQ:KPTI - Free Report) by 494.5% in the 2nd quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The fund owned 748,020 shares of the company's stock after purchasinOctober 14, 2024 | marketbeat.comKaryopharm Therapeutics Inc. (NASDAQ:KPTI) Receives Consensus Recommendation of "Moderate Buy" from BrokeragesShares of Karyopharm Therapeutics Inc. (NASDAQ:KPTI - Get Free Report) have been assigned a consensus rating of "Moderate Buy" from the five research firms that are presently covering the company, Marketbeat Ratings reports. One investment analyst has rated the stock with a hold rating and four haOctober 12, 2024 | marketbeat.comCubist Systematic Strategies LLC Buys New Shares in Karyopharm Therapeutics Inc. (NASDAQ:KPTI)Cubist Systematic Strategies LLC purchased a new position in Karyopharm Therapeutics Inc. (NASDAQ:KPTI - Free Report) during the 2nd quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The fund purchased 568,975 shares of the company's stocOctober 5, 2024 | marketbeat.comKaryopharm Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)October 1, 2024 | prnewswire.comAntengene Corporation Limited: Antengene Announces XPOVIO (selinexor) Approved for Commercialization in ThailandSeptember 23, 2024 | finanznachrichten.deAntengene Announces XPOVIO® (selinexor) Approved for Commercialization in ThailandSeptember 23, 2024 | prnewswire.comKaryopharm Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)September 3, 2024 | prnewswire.comKaryopharm to Participate at Upcoming Investor ConferencesSeptember 3, 2024 | prnewswire.comKaryopharm Therapeutics (NASDAQ:KPTI) Stock Crosses Below 200 Day Moving Average of $1.09Karyopharm Therapeutics (NASDAQ:KPTI) Share Price Crosses Below Two Hundred Day Moving Average of $1.09August 31, 2024 | marketbeat.comKaryopharm Therapeutics Inc. (NASDAQ:KPTI) Given Consensus Recommendation of "Moderate Buy" by AnalystsKaryopharm Therapeutics Inc. (NASDAQ:KPTI - Get Free Report) has been assigned an average rating of "Moderate Buy" from the five brokerages that are covering the company, MarketBeat reports. One research analyst has rated the stock with a hold recommendation and four have given a buy recommendatioAugust 23, 2024 | marketbeat.comKaryopharm Therapeutics (NASDAQ:KPTI) Stock Crosses Below Two Hundred Day Moving Average of $1.12Karyopharm Therapeutics (NASDAQ:KPTI) Shares Pass Below Two Hundred Day Moving Average of $1.12August 22, 2024 | marketbeat.comKPTI Sep 2024 0.500 put (KPTI240920P00000500)August 15, 2024 | finance.yahoo.comKaryopharm Therapeutics Inc. (KPTI) Q2 2024 Earnings Call TranscriptAugust 11, 2024 | seekingalpha.comWith 58% ownership, Karyopharm Therapeutics Inc. (NASDAQ:KPTI) boasts of strong institutional backingAugust 9, 2024 | finance.yahoo.comQ3 2024 EPS Estimates for Karyopharm Therapeutics Inc. Boosted by Analyst (NASDAQ:KPTI)Karyopharm Therapeutics Inc. (NASDAQ:KPTI - Free Report) - HC Wainwright lifted their Q3 2024 earnings per share (EPS) estimates for Karyopharm Therapeutics in a research report issued on Wednesday, August 7th. HC Wainwright analyst E. White now expects that the company will post earnings per shaAugust 9, 2024 | marketbeat.comKaryopharm Therapeutics (NASDAQ:KPTI) Upgraded to Buy by StockNews.comStockNews.com raised shares of Karyopharm Therapeutics from a "hold" rating to a "buy" rating in a research report on Thursday.August 8, 2024 | marketbeat.comKaryopharm Therapeutics (NASDAQ:KPTI) Receives Buy Rating from HC WainwrightHC Wainwright reissued a "buy" rating and issued a $7.00 target price on shares of Karyopharm Therapeutics in a research note on Wednesday.August 7, 2024 | marketbeat.comBarclays Keeps Their Buy Rating on Karyopharm Therapeutics (KPTI)August 7, 2024 | markets.businessinsider.com Get Karyopharm Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for KPTI and its competitors with MarketBeat's FREE daily newsletter. Email Address Download Our Tesla Ebook For Free (Ad)Like many of you, we here at the TradingPub are bullish on Tesla long term. We believe the company will continue to be a leader in technology, EVs and A.I. We also believe it’s share price will be rewarded in a big way… In fact, our #1 Tesla expert just published a brand new Ebook regarding Tesla’s future, and we’d like to send it to you at no cost. To claim your copy free of charge simply follow this link. KPTI Media Mentions By Week KPTI Media Sentiment Learn about the media sentiment score. Each headline receives a score ranging from 2 (good news) to -2 (bad news). Our company news sentiment scores track the average news sentiment of articles about each company over the most recent 7 days in order to identify companies that are receiving positive press. KPTI News Sentiment▼0.780.46▲Average Medical News Sentiment KPTI News Coverage Learn about the media coverage comparison. We track news headlines from hundreds of news outlets and tag them by company. This chart compares the number of articles about this company in the last seven days compared with the average number of articles about this company on a typical week. KPTI Articles This Week▼32▲KPTI Articles Average Week Get Karyopharm Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for KPTI and its competitors with MarketBeat's FREE daily newsletter. Email Address Related Companies and Tools Related Companies BioXcel Therapeutics News Today KalVista Pharmaceuticals News Today Valneva News Today Amylyx Pharmaceuticals News Today Ginkgo Bioworks News Today Alector News Today Q32 Bio News Today Contineum Therapeutics News Today Cryoport News Today Kamada News Today Headlines Tools Trending Media MentionsHigh Media Sentiment StocksLive News FeedMarketBeat OriginalsStock Ideas This page (NASDAQ:KPTI) was last updated on 11/21/2024 by MarketBeat.com Staff From Our PartnersThe Crypto That’s Making Wall Street SweatThe Crypto Wall Street Is Desperate to Hide It's happening now, right under everyone's radar. Big tech gian...Crypto 101 Media | SponsoredMissed Nvidia? Watch this ASAPThis little-known project that Bill Gates has been quietly working on that’s about to unleash an AI breakthrou...Brownstone Research | SponsoredMusk’s new company could top a trillion?The investment legend who predicted the rise of Bitcoin, Facebook and streaming services like Netflix… Just...Paradigm Press | Sponsored24/7 Automated Profits in CryptoWhat if you could make consistent daily profits in crypto with minimal effort? Beyond trading lies a vast w...Crypto Swap Profits | SponsoredCrypto’s next big bull run?Juan Villaverde may be America’s top crypto expert. And he says something big is coming for crypto – on Nov...Weiss Ratings | Sponsored“This Changes Everything” - Trump Hands Millions Massive IRS GiftNow it's your time to return the favor by taking advantage of this tax "revenge loophole." Because even as ...Colonial Metals | SponsoredTim Sykes’ Urgent Trade Alert: “Make this move now”WARNING: 80 Wall Street banks are gearing up for MASSIVE D.C. shock This $2 trillion D.C. shock is NOT abou...Timothy Sykes | SponsoredUnveiled: NVIDIA’s "Secret Royalty" ProgramDid you know that there's an investment that will give you the opportunity to collect "royalties" every time N...Behind the Markets | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Karyopharm Therapeutics Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Karyopharm Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Free KPTI Stock Alerts